This session focuses on the interconnected nature of cardiorenal metabolic (CRM) medicine and its importance in primary care. It describes how to identify those with CRM disorders, and how to undertake a holistic long term conditions review that incorporates personalised targets. It introduces the American Diabetes Society (ADA) and European Association for the Study of Diabetes (EASD) consensus report and with it, the recommendations around use of GLP-1 receptor agonists (GLP-1 RA) and SGLT2 inhibitors.
An educational grant was received by Boehringer Ingelheim Ltd for the production of this hub. Editorial and content decisions were made solely by the RCGP
Curriculum: Metabolic Problems and Endocrinology
Time to complete this course: 15 minutes
Date of publication: 15 January 2022
Mode: Course
Remove from search results: No
Podcast icon: No
Course index: Show
Section titles: Hide